
Arcellx (ACLX) Stock Forecast & Price Target
Arcellx (ACLX) Analyst Ratings
Bulls say
Arcellx is a clinical-stage biotechnology company that is poised for success with its innovative cell therapy approach in the treatment of various forms of cancer and other incurable diseases. The recently announced acquisition by collaborative partner Gilead for a significant sum further validates the potential of Arcellx's pipeline, particularly with the potential approval and successful launch of its lead candidate anito-cel in multiple myeloma patients. With a strong partnership and potential for significant long-term sales, Arcellx has a positive outlook for future growth and investors should continue to monitor its performance closely.
Bears say
Arcellx is facing significant risks that could negatively impact its valuation, including the loss of a key collaboration for anito-cel, potential competition for its lead programs and dilutive financing or acquisition risks. Additionally, its recent acquisition by Gilead may lead to pricing pressure from insurance companies and regulatory risks. While Arcellx has shown promising results with anito-cel, there is no guarantee it will gain market share in a competitive market for MM treatments.
This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.
Arcellx (ACLX) Analyst Forecast & Price Prediction
Start investing in Arcellx (ACLX)
Order type
Buy in
Order amount
Est. shares
0 shares